Search - tctmd.com

Displaying 381 - 400 of 420

Presentation TCT 2013

Coronary Endothelial Dysfunction Predicts Long-term Prognosis In Patients With Successful First Generation Drug-eluting Stents Implantation Without Residual Stenosis At Chronic...

Presenter: Shigenori Ito, Kosuke Nakasuka, Satoru Sekimoto, Kazuyuki Miyata, Masahiko Inomata, Takayuki Yoshida, Nozomu Tamai, Tomoaki Saeki, Shin Suzuki, Yoshimasa Murakami, Koichi Sato

January 31, 2013

Presentation TCT 2013

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

Presenter: Alexandre Benjo, Francisco Macedo, Emad Aziz, Francisco Nascimento, Fahad Javed, Eyal Herzog, Tyrone Collins, Christopher White

January 31, 2013

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 31, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

Presentation TCT 2012

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Presenter: Josep Gomez-Lara

October 23, 2012

Presentation TCT 2012

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Presenter: Ajay Kirtane

October 23, 2012

Presentation TCT 2012

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

Presenter: Michael Haude

October 23, 2012

Presentation TCT 2012

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Presenter: Thomas Zeller

October 23, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Presenter: Gary Ansel

October 22, 2012

News Conference News TCT 2012

Several Trials Highlight DES Comparisons

October 22, 2012

News Conference News TCT 2012

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

October 22, 2012

Presentation TCT 2012

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Presenter: Lawrence Garcia

October 22, 2012

Presentation TCT 2012

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

Presenter: Juan Luis Guti?rrez-Chico, Lorenz R?ber, Evelyn Regar, Takayuki Okamura, Carlo di Mario, Stephan Windecker, Gerrit-Anne van Es, Patrick W. Serruys

January 03, 2012

Presentation TCT 2012

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Presenter: Ted S. Trajceski, Lulzim Brovina, Zivko Petrovski, Blerim Zuna, Borce Petrovski

January 03, 2012

Presentation TCT 2012

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Presenter: Israel M. Barbash, Rebecca Torgusson, Itsik Ben-Dor, Gabriel Maluenda, Zhenyi Xue, William O. Suddath, Lowell F. Satler, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

January 03, 2012

Presentation TCT 2012

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Presenter: Hao Xu, Kytai T. Nguyen, Lance S. Terada, Eric Fuh, Joseph A. Garcia, Emmanouil S. Brilakis, Deepak L. Bhatt, Subhash Banerjee

January 03, 2012

Presentation TCT 2012

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Presenter: Boris Rudenko, Anatoly Savchenko, Serdgey Tereshchenko, Olga Cherkavskaya

January 03, 2012

Presentation TCT 2012

Pharmacokinetic Evaluation of Drug Eluting Stents in a Healthy and Atherosclerotic Rabbit Iliac Model

Presenter: Alexander Sheehy, Saami K. Yazdani, Ed Berger, Rosy S. Donn, Tu D. Ngo, Stephen Pacetti, Syed Hossainy, Frank D. Kolodgie, Renu Virmani

January 03, 2012

Advertisement

Coronary Endothelial Dysfunction Predicts Long-term Prognosis In Patients With Successful First Generation Drug-eluting Stents Implantation Without Residual Stenosis At Chronic...

Below-Knee Drug Eluting Stents Have Improved Patency, and Symptoms Compared to Bare Metal Stents: a meta-analysis

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Progress with Drug-Eluting Magnesium Resorbing Stents (BIOTRONIK): DREAMS 2-Year Results

After CTO Recanalization, What Is the Role of Drug-Eluting Devices, Covered Stents, Etc?

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Pro!

Several Trials Highlight DES Comparisons

Second-Generation DES Safer, More Effective Than BMS in STEMI at 1 Year

Debate I. Are Drug-Eluting Stents Now the Default Strategy for SFA Intervention? - Con!

Tissue coverage and neointimal hyperplasia of overlap vs. non-overlap segments in drug-eluting stents 9-13 months after implantation: in vivo-assessment with optical coherence...

The Nine-Month Outcomes of a Polymer-Free Drug-Eluting Stent (YUKON) Compared with Different Polymer Based Drug-Eluting Stents in Real-World Coronary Artery Lesions.

Safety and Efficacy of the Xience Everolimus Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice.

Response of Endothelial Progenitor Cells To Antiproliferative Drugs Currently Used in Drug Eluting Stents

Predictors Of Adverse Cardiac Events after PCI With GENOUS EPC-Coated Stents Compared To Drug Eluting Stents

Pharmacokinetic Evaluation of Drug Eluting Stents in a Healthy and Atherosclerotic Rabbit Iliac Model

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content